SynthesisFrontiers in microbiology2026
HPV prevalence in esophageal cancer: an updated systematic review and meta-analysis.
Synthesis in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epidemiology of Human Papillomavirus in the Middle East and North Africa: A Review of Genotypic Prevalence, Vaccination Challenges, and Non-Cervical Clinical Outcomes.Diseases (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Esophageal cancer (EC) is a significant global health concern. Human papillomavirus (HPV) has been proposed as a potential etiological factor, though its role, especially in esophageal adenocarcinoma (EAC), remains controversial. This study aims to systematically review and update the meta-analysis of HPV prevalence in both esophageal squamous cell carcinoma (ESCC) and EAC, and to assess the association between HPV infection and EC risk. Methods: A comprehensive literature search of PubMed, Scopus, and Web of Science was performed to identify studies published between January 1, 2000, and November 28, 2025 that reported HPV prevalence in EC, with a specific focus on both ESCC and EAC. Data on HPV genotypes, detection methods, and study characteristics were extracted and analyzed using random-effects models. Prevalence estimates were calculated for various detection methods, and meta-regression was used to identify sources of heterogeneity. Results: A total of 151 studies, including 18,913 EC cases, were analyzed. HPV prevalence in EC varied by detection method, with polymerase chain reaction (PCR)-based studies showing an overall prevalence of 31% (95% CI: 25%-36%). Regionally, East Asia exhibited the highest prevalence (44%, 95% CI: 35%-53%). HPV prevalence was consistently higher in ESCC (29%, 95% CI: 23%-36%) compared to EAC (16%, 95% CI: 5%-30%). HPV-16 was the most prevalent genotype, showing a stronger association with ESCC than EAC. Meta-regression identified geographic region as a significant predictor of HPV prevalence. A pooled odds ratio (OR) of 2.92 (95% CI: 2.19-3.90) indicates a strong association between HPV infection and increased EC risk. Conclusions: HPV infection-particularly HPV-16-is epidemiologically associated with esophageal cancer, with higher detection rates observed in ESCC. However, current evidence is insufficient to establish HPV as a definitive causal driver of EC, especially for EAC, due to the predominance of observational designs and limited mechanistic confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.